Global Antiobesity Market Forecast Highlights Growth Outlook And Key Trends Over 2025–2029

 What Market Size Is Projected For The Antiobesity Market By 2029?

 The antiobesity market size has grown strongly in recent years. It will grow from $3.74 billion in 2024 to $4.1 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing obesity prevalence, awareness and education, lifestyle changes, government initiatives.



 
 The antiobesity market size is expected to see strong growth in the next few years. It will grow to “ $5.94 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to market expansion, globalization. Major trends in the forecast period include research and development, patient-centric approaches, insurance coverage, technological advancements, digital health and telemedicine, novel drug therapies, bariatric surgery advancements, otc (over-the-counter) solutions, behavioral interventions, nutritional and weight management apps.
 
 Claim Your Free Report Sample Today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=3403&type=smp
 
 What Essential Growth Drivers Are Pushing The Antiobesity Market Forward?
 Obesity is a major public health concern globally. Globally, the prevalence rate of obesity is increasing every year. For instance, in May 2022, according to the World Obesity Atlas, a UK-based obesity organization, globally, it is estimated that more than 1 billion people will be suffering from obesity by 2030. This can be attributed to increased consumption of processed and unhealthy food, lack of physical activity, and lack of awareness of the risks of obesity. As a result, the demand for anti-obesity drugs is bound to increase in the future thus, driving the market growth.
 
 Which Segment Groups Play A Crucial Role In Outlining The Antiobesity Market’s Structure?
 The antiobesity market covered in this report is segmented — 
 
 1) By Drug Class: Peripherally Acting Anti-Obesity Drugs, Centrally Acting Anti-Obesity Drugs 
 2) By Type: Prescription Drugs (Rx), OTC Drugs 
 3) By Medication: Monotherapies, Polytherapies 
 
 Subsegments:
 1) By Peripherally Acting Anti-Obesity Drugs: Orlistat, Lorcaserin 
 2) By Centrally Acting Anti-Obesity Drugs: Phentermine, Topiramate, Naltrexone-Bupropion Combination, Liraglutide
 
 What Current Industry Trends Are Affecting The Performance Of The Antiobesity Market?
 Major companies operating in the anti-obesity drugs market are focusing on innovating new products, such as Mounjaro (tirzepatide), to provide reliable services to customers. Mounjaro (tirzepatide) is used as an anti-obesity drug for the treatment of adults with obesity or overweight with weight-related comorbidities. For instance, in October 2022, Eli Lilly and Company,a US-based pharmaceutical company, launched Mounjaro (tirzepatide), approved by the Food and Drug Administration (FDA), a US-based federal agency, as a fast track designation treatment. Mounjaro (tirzepatide) is an injectable form of anti-obesity drug used to help individuals struggling with obesity achieve their weight loss goals. This is used for adults with type 2 diabetes, along with diet and exercise, to improve blood sugar (glucose).
 
 Which Companies Represent The Key Strategic Forces Within The Antiobesity Market?
 Major companies operating in the antiobesity market include F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Novartis International AG, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Allergan Aesthetics, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Intas Pharmaceuticals Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd.
 
 Get Your In-Depth Antiobesity Market Report Now:
 https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report
 
 Which Regions Are Anticipated To Post The Highest CAGR In The Antiobesity Market?
 North America was the largest region in the anti-obesity market in 2024. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
 
 Contact Us:
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company

Comments

Popular posts from this blog

Global Next-Generation Advanced Batteries Market Outlook 2026-2030: Regional Growth and Sizing Insights

Intense Pulsed Light (IPL) Facial Rejuvenation Device Industry Projected to Experience Accelerated Growth by 2029

Global Aggregate Stockpile Drones Market Outlook 2026-2030: Regional Growth and Sizing Insights